Skip to content

The Effect of Atomoxetine on Cognitive Symptoms in Schizophrenia Patients

The Effect of Atomoxetine on Cognitive Symptoms in Schizophrenia Patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211219053452N1
Enrollment
40
Registered
2022-06-25
Start date
2022-04-21
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Patients are given 40 mg of atomoxetine daily for 8 weeks. Intervention 2: Control group: Similar tablets in terms of size and color of atomoxetine are prepared fr

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Schizophrenia Get a score of 61 or higher on the panss questionnaire

Exclusion criteria

Exclusion criteria: Simultaneous presence of other neurological disorders Any allergy to atomoxetine Patients who have received ECT in the last 6 weeks

Design outcomes

Primary

MeasureTime frame
Wechsler Short-Term Memory Test. Timepoint: Before the intervention and after 8 weeks of treatment. Method of measurement: Wechsler test.

Secondary

MeasureTime frame
Short-term memory expansive score, direct visual memory, reverse visual memory, direct auditory memory, auditory reverse memory. Timepoint: Before the intervention and after 8 weeks of treatment. Method of measurement: How to measure short-term memory, direct visual memory, reverse visual memory, direct auditory memory, auditory reverse memory using Wechsler test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Yousefi

Arak University of Medical Sciences

Fatemehyy75@gmail.com+98 86 3367 7022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026